PERSONALISED MEDICINE FOR BETTER HEALTH
About
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation and immunological disorders. We also pioneer in R&D projects centered on integrating biomarker targets in all phases of drug development, from preclinical to post-marketing. Plexision’s technology can be adapted to
- Assess disease risk for several immunological disorders.
- Predict the success of a drug for a specific patient.
- Develop dosing recommendations for new immunological drugs.
Our state-of-the-art laboratory is CLIA-certified and located in Pittsburgh, PA.
Contact
- +1 (855) 753-9474
- info@plexision.com
- 4424 Penn Ave., #202, Pittsburgh, PA 15224 USA
Products & Services
Personalized Diagnostic Testing
Pleximmune™
Pleximmune™ : an FDA-approved blood test to predict the risk of acute cellular rejection after liver or intestine transplantation in children.
PlexiMarkTM
Pleximmune™: an FDA-approved blood test to predict the risk of acute cellular rejection after liver or intestine transplantation in children.
PLEABMRTM
Pleximmune™: an FDA-approved blood test to predict the risk of acute cellular rejection after liver or intestine transplantation in children.
PleximmuneTM
Pleximmune™ : an FDA-approved blood test to predict the risk of acute cellular rejection after liver or intestine transplantation in children.
PlexCMV™
PlexCMV™: a blood test to measure the level of cellular immunity to Cytomegalovirus (CMV).
PlexEBV™
PlexEBV™ : a blood test to measure the level of cellular immunity to Epstein-Barr virus (EBV).
PlexBKV™
PlexBKV™ : a blood test to measure the level of cellular immunity to the BK variation of the polyomavirus.
Lymphocyte Subsets
A blood test to measure counts and relative frequencies of T-, B-and Natural-killer lymphocytes.
Antigen Stimulation
A blood test to measure T-cell immunity to common viruses, e.g. Cytomegalovirus and the Epstein-Barr virus.
Mitogen Stimulation
A blood test to measure a patient's general cellular immune response to common mitogens.
Antigen Stimulation
A blood test to measure T-cell immunity to common viruses, e.g. Cytomegalovirus and the Epstein-Barr virus.
Biomarkers
Plexision performs custom R and D projects aimed at integrating biomarker targets in all phases of drug development.
Plexision Blog
Check out our latest news, media, and event
related information
New blood test to predict antibody-mediated rejection to be presented at World Transplant Congress
SAN FRANCISCO — August, 2025. Antibody-mediated rejection causes severe graft injury and graft loss. New biomarkers are needed to manage this type of rejection. In a clinical trial conducted at three kidney transplant centers, the
PlexABMR™ test developed by Plexision predicted antibody-mediated rejection with positive and negative predictive values of 81% and 75%, respectively. Study results will be presented in San Francisco in early August, 2025 at the World Transplant Congress.
News
Read More
Rapid Six-Hour test panel to predict CMV infection and transplant injection.
Plexision, a biotechnology company, is offering the first blood test panel capable of reporting the risk of cytomegalovirus infection and transplant rejection within six hours after samples arrive at its reference laboratory.
News
Read More